

CLINICAL STUDY PROTOCOL

Grupo de Estudo da Doença Inflammatory Intestinal (GEDII)



Title: Study to investigate the correlation of fecal calprotectin with serum Drug levels and development of anti-dRug antibodyEs among adult patients with inflammatory bowel disease reCeiving anti-TNF-alfa treatment or Vedoluzimab treatment - Direct Study

Study code: **DIRECT**

Type of study: Observational

Date of protocol: 16 December 2014

Version no.: 1

Study Sponsor: Grupo de Estudo da Doença Inflammatory Intestinal (GEDII)

Name of Scientific Coordinator Prof. Fernando Magro

Signature and Date _____

Contact *Email: gedi@med.up.pt*

This document contains confidential information.
This document must not be disclosed to anyone other than the study staff and members of the independent ethics committee or regulatory agencies.
The information in this document cannot be used for any purpose other than the evaluation or conduct of the clinical investigation without the prior written consent from Grupo de Estudo da Doença Inflammatory Intestinal (GEDII)

PRINCIPAL INVESTIGATOR SIGNATURE PAGE *(to be signed by the PI from each participating center)*

Study Title: Study to investigate the correlation of fecal calprotectin with serum Drug levels and development of anti-dRug antibodyEs among adult patients with inflammatory bowel disease reCeiving anti-TNF-alfa treatment or Vedoluzimab treatment - Direct Study

Study Code: DIRECT

Protocol Version/Date: 1 /16 December 2014

Center Name: _____

Principal Investigator: _____

Name:

Academic degree:

Address:

Phone:

Email:

I, the undersigned, am responsible for the conduct of the study at this site and affirm that:

I understand and will conduct the study according to the protocol, any approved protocol amendments, and all applicable Health Authority requirements and national laws.

I will not deviate from the protocol without prior written permission from the GEDII, except where necessary to prevent immediate danger to the subject.

Signature

Date of Signature

INDEX

2	INTRODUCTION	8
2.1	INFLAMMATORY BOWEL DISEASE AND ANTI-TNF-ALFA THERAPIES	8
2.2	IMMUNOGENICITY AND SERUM ANTI-TNF-ALFA	8
2.3	FAECAL CALPROTECTIN	9
2.4	THE GEDII REGISTRY	10
2.5	RATIONALE	10
2.6	RESEARCH HYPOTHESIS	11
3	OBJECTIVES	11
3.1	PRIMARY OBJECTIVES	11
3.2	SECONDARY OBJECTIVES	11
4	STUDY DESIGN	12
5	STUDY TIMELINES	13
6	STUDY POPULATION	13
6.1	INCLUSION CRITERIA	13
6.2	EXCLUSION CRITERIA:	14
6.3	DISCONTINUATION FROM OBSERVATION PERIOD	14
7	INFORMATION TO BE COLLECTED	14
7.1	VARIABLES CAPTURED BY THE GEDII REGISTRY	14
7.2	PATIENT REPORTED OUTCOMES	16
7.3	ASSESSMENT OF SERUM ADALIMUMAB AND IFX LEVELS AND ANTIDRUG ANTIBODIES	17
7.4	ASSESSMENT OF BIOLOGICAL MARKER - FECAL CALPROTECTIN	17
8	EXPOSURE OF INTEREST	18
9	ENDPOINTS	19
9.1	PRIMARY ENDPOINT	19
9.2	SECONDARY ENDPOINTS	20
9.3	DEFINITIONS OF INTEREST	22
10	STATISTICAL ANALYSIS	25
10.1	GENERAL CONSIDERATIONS	25
10.2	SAMPLE SIZE	26
11	PHARMACOVIGILANCE	26
12	ETHICAL AND LEGAL ASPECTS	26
12.1	ETHICS	26
12.2	INFORMED CONSENT	26
12.3	STUDY DISCONTINUATION CRITERIA	26
13	QUALITY CONTROL	27
14	DATA HANDLING	27
14.1	CONFIDENTIALITY	27
14.2	DATA COLLECTION	27
14.3	STUDY ARCHIVE	28
14.4	PUBLICATION POLICY	28
15	REFERENCES	29
APPENDIX – CRONOGRAM A		

1. Sinopse

Title:	Study to investigate the correlation of fecal calprotectin with serum Drug levels and development of anti-drug antibodies among adult patients with inflammatory bowel disease receiving anti-TNF-alfa treatment or Vedoluzimab treatment - DIRECT Study
Study Code:	DIRECT
Scientific Coordinator:	Prof. Fernando Magro
Disease/Condition	Crohn's disease (CD) and Ulcerative Colitis (UC)
Rational	Thus far, there is no evidence if fecal calprotectin, a recognized biomarker in the context of IBDs, correlates with serum levels of anti-TNF-alfa therapies and with the development of antibodies against this class of drugs. Taking advantage of the valuable tool such as the GEDII Registry, the GEDII promoted a research to increase this knowledge. This study will follow a cohort of patients with CD or UC registered in the GEDII database and who are receiving adalimumab, golimumab, infliximab or vedoluzimab according to the approved label in Portugal. All patients, regardless of the anti-TNF-alfa treatment phase (induction or maintenance) at study inclusion, will be followed throughout a period of approximately 2 years. In addition, this study will investigate the correlation of serum drug levels with development of anti-drug antibodies among different subsets of the eligible population and the association of these indicators with physician- and patient-reported clinical outcomes.
Research hypothesis:	We hypothesize that fecal calprotectin levels will significantly correlate with serum levels of infliximab (IFX)/vedoluzimab (Vedo) and adalimumab/golimumab and with the development of antibodies against these drugs.
Primary Objectives:	Among biologic-naïve and non-naïve patients with CD or patients with UC registered in the GEDII Registry: <ul style="list-style-type: none"> • To explore the association of fecal calprotectin levels with serum adalimumab/golimumab levels throughout a period of 2 years since the start of observation period. • To explore the association of fecal calprotectin levels with the development of anti-adalimumab/anti-golimumab antibodies throughout a period of 2 years since the start of observation period. • To explore the association of fecal calprotectin levels with serum IFX/Vedo levels throughout a period of 2 years since the start of observation period. • To explore the association of fecal calprotectin levels with the development of anti-IFX/anti-Vedo antibodies throughout a period of 2 years since the start of observation period.
Secondary Objective(s):	Among biologic-naïve and non-naïve patients with CD or patients with UC registered in the GEDII Registry: <ul style="list-style-type: none"> • To explore the association of serum adalimumab/golimumab levels with the development of anti-adalimumab/anti-golimumab antibodies • To explore the association of serum adalimumab/golimumab levels with clinical activity throughout a period of 2 years since the start of observation period. • To explore the association of development of anti-adalimumab/anti-golimumab antibodies with clinical activity throughout a period of 2 years since the start of observation period. • To explore the association of serum adalimumab/golimumab levels with patient reported clinical outcome throughout a period of 2 years since the start of observation period. • To explore the association of development of anti-adalimumab/anti-golimumab antibodies with patient reported clinical outcome throughout a period of 2 years

	<p>since the start of observation period.</p> <ul style="list-style-type: none"> • To explore the association of therapeutic attitude with serum adalimumab/golimumab levels throughout a period of 2 years since the start of observation period. • To explore the association of therapeutic attitude with the development of anti-adalimumab/anti-golimumab antibodies throughout a period of 2 years since the start of observation period • To explore the association of serum IFX/Vedo levels with the development of anti-IFX/anti-Vedo antibodies • To explore the association of serum IFX/Vedo levels with clinical activity throughout a period of 2 years since the start of observation period. • To explore the association of development of anti-IFX/anti-Vedo antibodies with clinical activity throughout a period of 2 years since the start of observation period. • To explore the association of serum IFX/Vedo levels with patient reported clinical outcome throughout a period of 2 years since the start of observation period. • To explore the association of development of anti-IFX/anti-Vedo antibodies with patient reported clinical outcome throughout a period of 2 years since the start of observation period. • To explore the association of therapeutic attitude with serum IFX/Vedo levels throughout a period of 2 years since the start of observation period. • To explore the association of therapeutic attitude with development of anti-IFX/anti-Vedo antibodies throughout a period of 2 years since the start of observation period • To explore the association of clinical activity with patient reported clinical outcome among patients receiving adalimumab/golimumab throughout a period of 2 years since the start of observation period • To explore the association of clinical activity with patient reported clinical outcome among patients receiving IFX/Vedo throughout a period of 2 years since the start of observation period • To explore the association of calprotectin levels with clinical activity among the subgroup of patients who were co-medicated with azathioprine (AZA). • To explore the association of calprotectin levels with clinical activity among the subgroup of patients who were co-medicated with methotrexate (MTX).
<p>Study Design:</p>	<p>Multicenter, prospective, observational study designed to gather and analyze data on a consecutive cohort of subjects with CD or UC treated with anti-TNF-alfa therapies (adalimumab, golimumab or infliximab) or vedoluzimab. There is no imposed experimental intervention and these biologics will be managed taking into account the label approved in Portugal.</p> <p>The overall duration of observation for each patient is approximately two years from the time patient initiated the participation in the study (start of observation period), regardless of the anti-TNF-alfa treatment phase (induction or maintenance) at the time of inclusion in the study. Basal socio-demographic and clinical characteristics will be collected as well as physician- and patient- reported clinical outcomes (partial Mayo score or Harvey Bradshaw Index, according to the IBD studied) throughout several data collection time points. The data collection time points in this study will reflect the routine scheduled appointments, and will take into account the condition being studied (CD or UC) and the anti-TNF-alfa received (adalimumab, golimumab or IFX) or vedoluzimab.</p> <p>Fecal samples will be collected at the same time points as for the collection of blood samples (serum levels and anti-drug antibodies)</p>
<p>Inclusion Criteria:</p>	<p>Study subjects must fulfil the following criteria:</p> <ol style="list-style-type: none"> 1. Male or female patients, 18 years or older; 2. Patients who are registered in the GEDII Registry 3. Patients with moderate to severe active Crohn's disease or moderate to severe active Ulcerative Colitis;

	<p>4. Patients receiving anti-TNF-alfa agents (adalimumab/golimumab or infliximab) or vedoluzimab according to the local approved label, including:</p> <ul style="list-style-type: none"> ○ Biologic-naïve patients initiating induction with adalimumab/golimumab or infliximab/vedoluzimab at time of inclusion in the study or; ○ Patients already under maintenance treatment with adalimumab/golimumab or infliximab/vedoluzimab at time of inclusion in the study; <p>5. Patients who gave their informed consent.</p>
Exclusion Criteria:	<p>Subjects will be excluded if at least one of the following criteria is met:</p> <ol style="list-style-type: none"> 1. Patients who are not eligible for therapy with anti-TNF-alfa (adalimumab/golimumab or infliximab) or vedoluzimab; 2. Patients who are being treated with any investigational agent; 3. Patients who are not willing to comply with routine clinical appointments.
Expected number of subjects:	400 patients
Expected number of sites:	Approximately 10 centers are expected to participate.
Subject selection:	All subjects who meet eligibility criteria and give their written informed consent to participate will be consecutively enrolled.
Exposure of interest:	Adalimumab (Humira), golimumab, infliximab (Remicade) and vedoluzimab are the exposures of interest. These products will be used according to the approved label.
Main data collected:	Socio-demographic and medical history and UC/CD related data will be collected for all eligible patients. Clinical activity of disease, serum adalimumab/golimumab and IFX/vedoluzimab, anti-drug antibodies and fecal calprotectin levels will be measured at first appointment and throughout the data collection time points of the follow up period (up to month 24).
Endpoints	<p>Primary endpoints:</p> <p>In the subset of biologic-naïve and non-naïve patients with active, moderate to severe CD receiving adalimumab:</p> <ul style="list-style-type: none"> •Fecal calprotectin levels and serum adalimumab levels at each data collection time points •Fecal calprotectin levels and presence of anti-adalimumab antibodies (+ or -) at each data collection time points <p>In the subset of biologic-naïve and non-naïve patients with active, moderate to severe CD receiving IFX/Vedo:</p> <ul style="list-style-type: none"> •Fecal calprotectin levels and serum IFX/Vedo levels at each data collection time points •Fecal calprotectin levels and presence of anti-IFX/anti-Vedo antibodies (+ or -) at each data collection time points <p>In the subset of biologic-naïve and non-naïve patients with active, moderate to severe UC receiving adalimumab/golimumab:</p> <ul style="list-style-type: none"> •Fecal calprotectin levels and serum adalimumab/golimumab levels at each data collection time points •Fecal calprotectin levels and presence of anti-adalimumab/anti-golimumab antibodies (+ or -) at each data collection time points <p>In the subset of biologic-naïve and non-naïve patients with active, moderate to severe UC receiving IFX/Vedo:</p> <ul style="list-style-type: none"> •Fecal calprotectin levels and serum IFX/Vedo levels at each data collection time points •Fecal calprotectin levels and presence of anti-IFX/anti-Vedo antibodies (+ or -) at each data collection time points <p>Secondary endpoints:</p> <p>In the subset of biologic-naïve and non-naïve patients with active, moderate to severe CD receiving adalimumab:</p> <ul style="list-style-type: none"> •Serum adalimumab levels and anti-adalimumab antibodies (+ or -) at each data collection time points. •Serum adalimumab levels and clinical activity (HBI) at each data collection time points. •Anti-adalimumab antibodies (+ or -) and clinical activity (HBI) at each data

	<p>collection time points.</p> <ul style="list-style-type: none"> •Serum adalimumab levels and patient-reported clinical activity (Patient reported HBI) at each data collection time points. •Anti-adalimumab antibodies (+ or -) and patient-reported clinical activity (Patient reported HBI) at each data collection time points. •Therapeutics administered for CD (name and dose) and serum adalimumab levels. •Therapeutics administered for CD (name and dose) and anti-adalimumab antibodies (+ or -). <p>In the subset of biologic-naïve and non-naïve patients with active, moderate to severe CD receiving IFX/Vedo:</p> <ul style="list-style-type: none"> •Serum IFX/Vedo levels and anti-IFX/anti-Vedo antibodies (+ or -) at each data collection time points •Serum IFX/Vedo levels and clinical activity (HBI) at each data collection time points. •Anti-IFX/anti-Vedo antibodies (+ or -) and clinical activity (HBI) at each data collection time points. •Serum IFX/Vedo levels and patient-reported clinical activity (Patient reported HBI) at each data collection time points. •Anti-IFX/anti-Vedo antibodies (+ or -) and patient-reported clinical activity (Patient reported HBI) at each data collection time points. •Therapeutics administered for CD (name and dose) and serum IFX/Vedo levels. •Therapeutics administered for CD (name and dose) and anti-IFX/anti-Vedo antibodies (+ or -). <p>In the subset of biologic-naïve and non-naïve patients with active, moderate to severe UC receiving adalimumab/golimumab:</p> <ul style="list-style-type: none"> •Serum adalimumab/golimumab levels and anti-adalimumab/anti-golimumab antibodies (+ or -) at each data collection time points •Serum adalimumab/golimumab levels and clinical activity (partial Mayo Score) at each data collection time points. <p>Partial Mayo Score: Mayo score excluding the endoscopy subscore (range: 0-9)</p> <ul style="list-style-type: none"> •Anti-adalimumab/anti-golimumab antibodies (+ or -) and clinical activity (partial Mayo Score) at each data collection time points. •Serum adalimumab/golimumab levels and patient-reported clinical activity (Patient reported partial Mayo Score) at each data collection time points. •Anti-adalimumab/anti-golimumab antibodies (+ or -) and patient-reported clinical activity (Patient reported partial Mayo Score) at each data collection time points. •Therapeutics administered for UC (name and dose) and serum adalimumab/golimumab levels. •Therapeutics administered for UC (name and dose) and anti-adalimumab/anti-golimumab antibodies (+ or -) <p>In the subset of biologic-naïve and non-naïve patients with active, moderate to severe UC receiving IFX/Vedo:</p> <ul style="list-style-type: none"> •Serum IFX/Vedo levels and anti-IFX/anti-Vedo antibodies (+ or -) at each data collection time points •Serum IFX/Vedo levels and clinical activity (partial Mayo Score) at each data collection time points. •Anti-IFX/anti-Vedo antibodies (+ or -) and clinical activity (partial Mayo Score) at each data collection time points. •Serum IFX/Vedo levels and patient-reported clinical activity (Patient reported partial Mayo Score) at each data collection time points. •Anti-IFX/anti-Vedo antibodies (+ or -) and patient-reported clinical activity (Patient reported partial Mayo Score) at each data collection time points. •Therapeutics administered for UC (name and dose) and serum IFX/Vedo levels. •Therapeutics administered for UC (name and dose) and anti-IFX/anti-Vedo antibodies (+ or -) <p>In the subsets of biologic-naïve and non-naïve patients patients with active, moderate to severe CD receiving adalimumab + azathioprine or adalimumab + methotrexate or IFX/Vedo + azathioprine or IFX/Vedo + methotrexate:</p> <ul style="list-style-type: none"> •Fecal calprotectin levels and serum adalimumab levels at each data collection time points •Fecal calprotectin levels and presence of anti-adalimumab antibodies (+ or -) at each data collection time points
--	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

	<ul style="list-style-type: none"> •Fecal calprotectin levels and serum IFX/Vedo levels at each data collection time points •Fecal calprotectin levels and presence of anti-IFX/anti-Vedo antibodies (+ or -) at each data collection time points <p>In the subsets of biologic-naïve and non-naïve patients with active, moderate to severe UC receiving adalimumab/golimumab + azathioprine or adalimumab/golimumab + methotrexate or IFX/Vedo + azathioprine or IFX/Vedo + methotrexate:</p> <ul style="list-style-type: none"> •Fecal calprotectin levels and serum adalimumab/golimumab levels at each data collection time points •Fecal calprotectin levels and presence of anti-adalimumab/anti-golimumab antibodies (+ or -) at each data collection time points •Fecal calprotectin levels and serum IFX/Vedo levels at each data collection time points •Fecal calprotectin levels and presence of anti-IFX/anti-Vedo antibodies (+ or -) at each data collection time points <p>In the subset of biologic-naïve and non-naïve patients with active, moderate to severe CD:</p> <ul style="list-style-type: none"> •Physician's reported HBI and patient-reported HBI (overall and according to anti-TNF-alfa or vedoluzimab) <p>In the subset of biologic-naïve and non-naïve patients with active, moderate to severe UC:</p> <ul style="list-style-type: none"> •Physician's reported partial Mayo Score at each data collection time points and patient-reported partial Mayo Score (overall and according to anti-TNF-alfa or vedoluzimab)
Statistical methods	<p>The association between two quantitative variables will be performed through Pearson correlation coefficient or Spearman correlation coefficient, in case the normality assumption is not verified. The association of two categorical variables will be tested through the Chi-Square test or Fisher Exact test (if applicable).</p> <p>The comparison of two independent samples in respect to quantitative variables will be performed through t-test for independent samples or the Mann-Whitney non-parametric test, according to the assumption validations of the statistical test (if applicable).</p> <p>The association between quantitative variables and a categorical binary variable will be analyzed by Area Under the ROC Curve.</p> <p>The concordance kappa will be used binary variables, if applicable.</p> <p>For each subset, the proportion of patients with active disease, clinical response, clinical remission (physician and patient reported HBI or Partial Mayo), presence of anti-drug antibodies at each data collection time points will be summarized using 95% confidence intervals.</p> <p>Exploratory Generalized Estimated Equations with AR1 correlation structure in time, to account for the within-subject correlations, will be used to explore the association between fecal calprotectin levels and serum drug levels (dependent variable) as well as the association of fecal calprotectin levels with the presence of antidrug antibodies (dependent variable), throughout the follow up period.</p> <p>The impact of immunogenicity on the efficacy of adalimumab or IFX will also be exploratory assessed by associating serum drug levels and anti-drug antibodies in respect to the outcomes, need for dose escalation, and discontinuation rate at the predetermined time points.</p>
Overall Study Duration:	The overall duration of the study is three years (1 year of recruitment + 2-year observation period).
Study timelines:	The study is expected to start during the 1 st Quarter of 2015. Study closure is expected to occur 2 nd Quarter of 2018.

2 INTRODUCTION

2.1 INFLAMMATORY BOWEL DISEASE AND ANTI-TNF-ALFA THERAPIES

Inflammatory bowel disease (IBD) is a chronic and disabling condition with an increasing incidence in southern Europe. The etiology of IBD remains unknown, but the characteristic disproportionate inflammatory response in the gut may develop through various mechanisms at the cellular and subcellular level.¹ Ulcerative colitis (UC) and Crohn's disease (CD) represent the two main types of IBD.

Ulcerative colitis is a relapsing non-transmural inflammatory disease that is restricted to the colon. Patients typically present with bloody diarrhoea (often nocturnal and postprandial), passage of pus, mucus, or both, and abdominal cramping during bowel movements. Crohn's disease is a relapsing, transmural inflammatory disease of the gastrointestinal mucosa that can affect the entire gastrointestinal tract from the mouth to the anus. Typical presentations include the discontinuous involvement of various portions of the gastrointestinal tract and the development of complications including strictures, abscesses, or fistulas.²

In Portugal, the prevalence of IBDs increased from 86 to 146 persons per 100 000 inhabitants between 2003 and 2007. Within the same timeframe, the prevalence of UC and CD increased from 42 to 71 persons per 100 000 inhabitants and from 43 to 73 persons per 100 000 inhabitants, respectively. IBDs are more prevalent among women.³

Tumor necrosis factor α (TNF) is a proinflammatory cytokine that plays a central role in the pathogenesis of CD and UC.⁴ Abundantly expressed in the gastrointestinal tracts of patients with IBD⁵, TNF is believed to contribute to intestinal mucosal inflammation through several mechanisms, including disruption of the epithelial barrier, induction of apoptosis of the villous epithelial cells, and secretion of chemokines from intestinal epithelial cells.⁴

Over the past decade, anti-TNF agents have dramatically influenced the treatment of patients with refractory IBD. These agents have been developed as monoclonal antibodies (mAbs) and are directed against TNF molecules.

Infliximab (IFX, Remicade) is a chimeric immunoglobulin G (IgG) human (75%)/murine (25%) mAb administered by intravenous infusion (5 mg/kg), indicated for induction and maintenance of remission in adult and pediatric CD and for induction and maintenance of remission of UC.⁶ IFX is also approved for other chronic inflammatory conditions such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.

Adalimumab (Humira) is a recombinant, fully human, subcutaneously delivered immunoglobulin G1 monoclonal antibody. Four randomized trials have demonstrated that adalimumab is effective and safe for the induction and maintenance of clinical remission in patients with active moderate to severe CD.⁷⁻¹⁰ Recently several studies have investigated the efficacy and safety of adalimumab in patients with UC. Adalimumab has been approved by the Food and Drug Administration for inducing and sustaining clinical remission in adult patients with moderate to severe active ulcerative colitis who have had an inadequate response to immunosuppressants such as corticosteroids, azathioprine or 6-mercaptopurine (6-MP).¹¹⁻¹³

2.2 IMMUNOGENICITY AND SERUM ANTI-TNF-ALFA

Despite the proven efficacy of anti-TNF-alfa agents in the maintenance of remission in IBDs, a significant proportion of patients lose their clinical response over time despite maintenance treatment.¹⁴ This loss of response occurs in up to 70% of patients treated with IFX, and usually requires escalation of dosing or change in anti-TNF-alfa agent to re-capture clinical remission.^{15,16}

There are several explanatory mechanisms to loss of response to anti-TNF-alfa agents. However, immunogenicity to the antibody itself appears to be a commonly identified factor.^{6,17,18}

Since IFX is a chimeric mouse–human IgG1 molecule, antibodies to IFX are primarily directed against the murine F(ab)2 fragment of the agent.^{19,20} Anti-drug antibodies are reported to develop in 8–60% of patients with inflammatory bowel disease (IBD), depending on IFX dosing schedule, administration of concomitant steroids or immunomodulators and the method of measuring anti-drug antibodies in the blood.^{18,19,21} These antibodies can appear as soon as after the first infusion of the drug, and can persist in the blood stream for up to 1–4.5 years even after discontinuation of therapy.^{22,23}

Although human antibodies like adalimumab are potentially less immunogenic, the Classic II study showed that 2%-4% patients with CD developed antibodies against adalimumab⁹ but their influence in clinical outcome has not yet been clarified. More recently, one study conducted in patients who previously failed to respond to IFX and received adalimumab as maintenance therapy showed that 9.2% of patients developed antibodies against adalimumab.¹⁸

Higher IFX trough levels have been associated with sustained clinical remission in several studies.²³⁻²⁵ Seow et al. (2010)²⁵ showed that in their UC population treated with scheduled IFX dosing, detectable IFX trough was associated with significant positive predictive value for clinical remission, endoscopic improvement, and avoidance of colectomy. Similarly, Maser et al. (2006)²⁴ showed that in a subgroup of patients on maintenance therapy, higher IFX levels were associated with a significant improvement of clinical remission, CRP, and endoscopic healing. Steenholdt et al. (2012)²³ investigated a mixed population of IBD patients and found that higher IFX trough levels were associated with maintenance of response. They were also able to determine clinically relevant threshold values for trough IFX and anti-IFX antibodies concentrations.

The association of development of antibodies against anti-TNF-alfa therapies with trough serum drug levels and response to these drugs has been inconsistent due to a lack of standardization of methods of measurement of serum drug levels or antidrug antibodies. For instance, the presence of detectable drug in the serum typically impairs the performance of a solid-phase enzyme-linked immunosorbent assay (ELISA) and western blot.¹⁹ With classic Enzyme-linked immunosorbent assay (ELISA), antibodies remain undetectable as long as the drug is present in the blood. The type of detection assays also affects the reported incidence of antidrug antibodies.²⁶

Studies have shown that clearance of IFX is greatly increased in the presence of antibodies to infliximab, and results in low IFX trough levels.^{19,27,28} Low serum IFX levels have been associated with a lack of clinical response in both CD and UC (16,21,22).^{23,24,29} Multiple studies in IBD patients have linked the development of antidrug antibodies with loss of treatment response, shorter duration of response, and infusion reactions.^{19,21,25,29,30} Conversely, others have shown no difference in clinical outcomes between antidrug antibodies-positive or antidrug antibodies-negative patients.^{8,24}

Karminis et al. (2009)¹⁸ investigated the association between adalimumab trough serum concentration and treatment outcome and between the development of antibodies against adalimumab and trough serum concentration. This study showed that early discontinuation of therapy correlated with lower adalimumab trough serum concentration. In addition, long-term treatment discontinuation of adalimumab was associated to lower trough serum concentration, although there was no direct relationship between short term efficacy and trough serum concentration.

2.3 FECAL CALPROTECTIN

Given the invasive nature of endoscopy, the implementation of an easy, non-invasive method to support the pre-diagnostic screening and monitoring of disease activity is essential.

Fecal calprotectin has been shown to be useful in the diagnosis of IBD, correlates with mucosal disease activity and can help to predict response to treatment or relapse. In IBD, the presence of

active gut inflammation is associated with migration of leucocytes, including neutrophils, to the gut mucosa.³¹ As a result the fecal stream contains increased levels of these inflammatory proteins including calprotectin. fecal calprotectin has been shown to differentiate quiescent from active disease in both patients with CD and UC.^{32,33}

A meta-analysis including 30 prospective studies showed that the sensitivity and specificity of fecal calprotectin in diagnosing IBDs could reach up to 95% and 91%, respectively.³⁴ Fecal calprotectin also showed to be a reliable surrogate marker of treatment response.³⁵ Calprotectin levels decreases significantly after IFX treatment for 12 weeks, and it correlates with endoscopic index of severity (CDEIS).³⁶ Røseth et al. show that fecal calprotectin levels correlated with endoscopic mucosal healing.³⁷ A meta-analysis focusing on fecal calprotectin in IBD relapse showed that the sensitivity and specificity when predicting the relapse are 78% and 73%, separately.³⁸

To our knowledge, there is no evidence if fecal calprotectin levels correlate with serum levels of anti-TNF-alfa drugs or with the development of anti-drug antibodies.

2.4 THE GEDII REGISTRY

Patient registries are a powerful tool to observe the course of disease, understand variations in treatment and outcomes, to assess effectiveness, to monitor safety and harm and to examine factors that influence prognosis and quality of life. It also allows to describe care patterns and to measure quality of care.

From a clinician's perspective, registries can collect data about disease presentation and outcomes on large numbers of patients rapidly, thereby producing a real-world picture of disease, current treatment practices, and outcomes. A registry might also provide data that can be used to assess the degree to which clinicians are managing a disease in accordance with evidence based guidelines, focus attention on specific aspects of a particular disease that might otherwise be overlooked, or provide data for clinicians to compare themselves with their peers. Overall, the use of patient registries appears to be active and growing.⁸

The "Grupo de Estudo da Doença Inflamatória Intestinal" (GEDII) Registry was created on 2005 and allows the regular and systematic capture of socio-demographic and clinical characteristics of patients diagnosed with IBDs (DC, UC and indeterminate UC). The Registry also captures the clinical and safety outcomes, treatments and the use of health resources.

So far, the Registry covers 20 gastroenterology departments of public hospitals. As of April 2014, the Registry comprised a total of 2500 patients.

2.5 RATIONALE

Thus far, there is no evidence if fecal calprotectin, a recognized biomarker in the context of IBDs, correlates with serum levels of anti-TNF-alfa therapies and with the development of antibodies against this class of drugs. Taking advantage of the valuable tool such as the GEDII Registry, the GEDII promoted a research to increase this knowledge. This study will follow a cohort of patients with CD or UC registered in the GEDII database and who are receiving adalimumab or infliximab according to the approved label in Portugal. All patients, regardless of the anti-TNF-alfa treatment phase (induction or maintenance) at study inclusion, will be followed throughout a period of approximately 2 years. In addition, this study will investigate the correlation of serum drug levels with development of anti-drug antibodies among different subsets of the eligible population and the association of these indicators with physician- and patient-reported clinical outcomes.

2.6 RESEARCH HYPOTHESIS

We hypothesize that fecal calprotectin levels will significantly correlate with serum levels of IFX/Vedo and adalimumab/golimumab and with the development of antibodies against these drugs.

3 OBJECTIVES

3.1 PRIMARY OBJECTIVES

Among biologic-naïve and non-naïve patients with CD or patients with UC registered in the GEDII Registry:

- To explore the association of fecal calprotectin levels with serum adalimumab/golimumab levels throughout a period of 2 years since the start of observation period.
- To explore the association of fecal calprotectin levels with the development of anti-adalimumab/anti-golimumab antibodies throughout a period of 2 years since the start of observation period.
- To explore the association of fecal calprotectin levels with serum IFX/Vedo levels throughout a period of 2 years since the start of observation period.
- To explore the association of fecal calprotectin levels with the development of anti-IFX/anti-Vedo antibodies throughout a period of 2 years since the start of observation period.

3.2 SECONDARY OBJECTIVES

Among biologic-naïve and non-naïve patients with CD or patients with UC registered in the GEDII Registry:

- To explore the association of serum **adalimumab/golimumab levels** with the development of **anti-adalimumab/anti-golimumab antibodies**
- To explore the association of serum **adalimumab/golimumab levels** with **clinical activity** throughout a period of 2 years since the start of observation period.
- To explore the association of development of **anti-adalimumab/anti-golimumab antibodies** with **clinical activity** throughout a period of 2 years since the start of observation period.
- To explore the association **of serum adalimumab/golimumab** levels with **patient reported clinical outcome** throughout a period of 2 years since the start of observation period.
- To explore the association of development of **anti-adalimumab/anti-golimumab antibodies** with **patient reported clinical outcome** throughout a period of 2 years since the start of observation period.
- To explore the association **of therapeutic attitude** with **serum adalimumab/golimumab** levels throughout a period of 2 years since the start of observation period.
- To explore the association of **therapeutic attitude** with the development of **anti-adalimumab/anti-golimumab antibodies** throughout a period of 2 years since the start of observation period

- To explore the association of serum **IFX/Vedo levels** with the development of **anti-IFX/anti-Vedo antibodies**
- To explore the association of serum **IFX/Vedo levels** with **clinical activity** throughout a period of 2 years since the start of observation period.
- To explore the association of development of **anti-IFX/anti-Vedo antibodies** with **clinical activity** throughout a period of 2 years since the start of observation period.
- To explore the association of **serum IFX/Vedo levels** with **patient reported clinical outcome** throughout a period of 2 years since the start of observation period.
- To explore the association of development of **anti-IFX/anti-Vedo antibodies** with **patient reported clinical outcome** throughout a period of 2 years since the start of observation period.
- To explore the association of **therapeutic attitude** with **serum IFX/Vedo levels** throughout a period of 2 years since the start of observation period.
- To explore the association of **therapeutic attitude** with development of **anti-IFX/anti-Vedo antibodies** throughout a period of 2 years since the start of observation period
- To explore the association of **clinical activity** with **patient reported clinical outcome** among patients receiving **adalimumab/golimumab** throughout a period of 2 years since the start of observation period
- To explore the association of **clinical activity** with **patient reported clinical outcome** among patients receiving **IFX/Vedo** throughout a period of 2 years since the start of observation period
- To explore the association of **calprotectin** levels with **clinical activity** among the subgroup of patients who were co-medicated with **azathioprine (AZA)**.
- To explore the association of **calprotectin** levels with **clinical activity** among the subgroup of patients who were co-medicated with **methotrexate (MTX)**.

4 STUDY DESIGN

This is a multicenter, prospective, observational study designed to gather and analyze data on a consecutive cohort of subjects with CD or UC treated with anti-TNF-alfa therapies (adalimumab, golimumab or infliximab) or vedoluzimab. There is no imposed experimental intervention and these biologics will be managed taking into account the label approved in Portugal.

A prospective, observational study is considered an appropriate tool to evaluate the impact of exposures of interest in real-world outcomes and an opportunity to explore biomarkers that can potentially predict clinical response in these settings.

The study will analyze a consecutive sample of 400 patients who are registered in the GEDII Registry and who fulfill the protocol's eligibility criteria. The recruitment period is 12 months but may be extended if the target number of participants is not achieved within the defined timeframe.

The overall duration of observation for each patient is approximately two years from the time patient initiated the participation in the study (start of observation period), regardless of the anti-TNF-alfa treatment phase (induction or maintenance) at the time of inclusion in the study. Basal socio-demographic and clinical characteristics will be collected as well as physician- and patient- reported

clinical outcomes (partial Mayo score or Harvey Bradshaw Index, according to the IBD studied) throughout several data collection time points. The data collection time points in this study will reflect the routine scheduled appointments, and will take into account the condition being studied (DC or UC) and the anti-TNF-alfa received (adalimumab, golimumab or IFX) or vedoluzimab - See Cronogram A and B in Appendix.

Blood samples for assessment of serum levels of adalimumab/golimumab and IFX/Vedo and antibodies against these drugs will be collected during scheduled appointments to the hospital as follows:

- Patients initiating induction with infliximab/vedoluzimab at study inclusion: Day 1, week 6 and then every 8 weeks up to week 102 (or every 6 weeks, if required);
- Patients in maintenance with infliximab/vedoluzimab at study inclusion: Week 'number' (number of weeks since patient started infliximab/vedoluzimab) and every 8 weeks thereafter, until completing the 24-month follow up period (or every 6 weeks, if required);
- Patients initiating induction with adalimumab/golimumab at study inclusion: Day 1, week 6 and then every 12 weeks up to week 96;
- Patients in maintenance with adalimumab/golimumab at study inclusion: Week 'number' (number of weeks since patient started adalimumab/golimumab) and every 12 weeks thereafter, until completing the 24-month follow up period.

Fecal samples will be collected at the same time points as for the collection of blood samples (serum levels and anti-drug antibodies), according to the anti-TNF-alfa received. Fecal and blood samples should always be collected prior to infusion of adalimumab/golimumab or IFX/Vedo during the scheduled appointment.

A total of 10 centers are expected to participate.

5 STUDY TIMELINES

The study is expected to start during the 1st Quarter of 2015.

The overall duration of the study is three years (1 year of recruitment + 2-year observation period).

6 STUDY POPULATION

6.1 INCLUSION CRITERIA

Study subjects must fulfill the following criteria:

1. Male or female patients, 18 years or older;
2. Patients who are registered in the GEDII Registry
3. Patients with moderate to severe active Crohn's disease or moderate to severe active Ulcerative Colitis;
4. Patients receiving anti-TNF-alfa agents (adalimumab, golimumab or infliximab) or vedoluzimab according to the local approved label, including:
 - Biologic-naïve patients initiating induction with adalimumab, golimumab, infliximab or vedoluzimab at time of inclusion in the study **or**;

- Patients already under maintenance treatment with adalimumab, golimumab infliximab or vedoluzimab at time of inclusion in the study;
5. Patients who gave their informed consent.

6.2 EXCLUSION CRITERIA:

Subjects will be excluded if at least one of the following criteria is met:

1. Patients who are not eligible for therapy with anti-TNF-alfa (adalimumab, golimumab or infliximab) or vedoluzimab;
2. Patients who are being treated with any investigational agent;
3. Patients who are not willing to comply with routine clinical appointments.

6.3 DISCONTINUATION FROM OBSERVATION PERIOD

In this study, patients will be followed up to a maximum period of 24 months. However, observation may be stopped prior to the 24 months for different reasons including, but not limited to:

- Patient discontinues the exposure of interest (adalimumab or infliximab)
- Protocol violation
- Lost to follow up
- Patient withdrawal of consent
- Pregnancy
- Death

In the case observation period is stopped prior to the 24 months, the date of study discontinuation, last intake of adalimumab/golimumab or IFX/vedoluzimab, and the reason for discontinuation should be recorded in the electronic CRF. In addition, all efforts should be made to assess calprotectin levels, serum drug levels and antidrug antibodies.

7 INFORMATION TO BE COLLECTED

7.1 VARIABLES CAPTURED BY THE GEDII REGISTRY

The GEDII Registry allows the collection of socio-demographic, clinical characteristics and outcomes of patients diagnosed with IBDs.

For the purpose of this study the following variables will be obtained from the Registry:

Basal characteristics

- Date of birth

- Sex
- Height
- Weight
- BMI
- Smoking status
- Pregnancy status (if applicable)
- Diagnosis (UC, CD) and date
- Date of start of symptoms
- Familial history of IBDs
- Disease presentation (abdominal, constitutional, abdominal + constitutional, anal disease, acute abdomen, fever, anemia, extra-intestinal manifestation, abdominal mass, similar presentation to UC)
- Clinical course
- Steroid behavior:
 - Steroid-dependent disease, defined as patients who are either: i) unable to reduce steroids below the equivalent of prednisolone 10 mg/day (or budesonide below 3 mg/day) within 3 months of starting steroids, without recurrent active disease, or ii) who have a relapse within 3 months of stopping steroids. This definition of steroid-dependence requires that the total duration of steroids does not exceed 3 months before a threshold equivalent to prednisolone 10 mg/day is reached. Patients are still considered steroid-dependent if they relapse within 3 months of stopping steroids.³⁹
 - Steroid-refractory disease defined as patients who have active disease despite prednisolone of up to 0.75 mg/kg/day over a period of 4 weeks.³⁹
- Harvey Bradshaw score (5 items: general well-being, abdominal pain, number of liquid or soft stools per day, abdominal mass and complications)
- Partial Mayo score (UC activity): stool frequency, rectal bleeding, physician's global assessment.
- Routine laboratory parameters (hemoglobin, leukocytes, neutrophils, eosinophiles, basophiles, monocytes, lymphocytes, erythrocyte sedimentation rate, CRP, ferritin, iron and transferrin)
- Colitis location (rectum, rectum-sigmoide, colon distal, pancolitis)
- First episode (Montreal classification)
- Location of CD
- Location of CD, by segment
- CD classification, based on prognosis
- Anal lesion (strictures, abscesses, or fistulas)
- Ileal disease (achievement $\geq 1m$, $<1m$)
- Extra-abdominal manifestations
- Name and dose of anti-TNF-alfa (adalimumab, golimumab or IFX) or vedoluzimab, date of start (first infusion - Day 1)
- Concomitant therapies (since the first infusion - Day 1)
- Assessment of serum levels of adalimumab/golimumab or IFX/vedoluzimab (prior to infusion) - $\mu\text{g/mL}$
- Assessment of anti-drug antibodies of adalimumab/golimumab or IFX/vedoluzimab (prior to infusion)
- Assessment of fecal calprotectin levels ($\mu\text{g/g}$)
- Patient reported outcomes (Harvey Bradshaw Index - CD or Partial Mayo score - UC)

Information to be collected during induction therapy with adalimumab/golimumab (week 2 and 6) and maintenance therapy (every 12 weeks up to week 96 or until completion of the 24-month follow up period) - see Cronogram A:

- Weight and BMI
- Comorbidities
- Clinical activity (physician reported Harvey Bradshaw Index - CD or Partial Mayo score – UC)
- Dose of adalimumab/golimumab
- Concomitant therapies, if changed since previous appointment
- Routine laboratory parameters (hemoglobin, leukocytes, neutrophils, eosinophiles, basophiles, monocytes, lymphocytes, erythrocyte sedimentation rate, CRP, ferritin, iron and transferrin)
- Assessment of serum levels of adalimumab/golimumab (prior to infusion)
- Assessment of anti-drug antibodies of adalimumab/golimumab (prior to infusion)
- Assessment of fecal calprotectin levels (prior to infusion)
- Patient reported outcomes (Harvey Bradshaw Index - CD or Partial Mayo score - UC)
- Status: ongoing/discontinuation. If discontinued, reason.

Information to be collected during induction therapy with IFX/vedoluzimab (week 2 and 6) and maintenance therapy (every 8 weeks up to week 102 or until completion of the 24-month follow up period)* - see Cronogram B:

- Weight and BMI
- Comorbidities
- Clinical activity (physician reported Harvey Bradshaw Index - CD or Partial Mayo score – UC)
- Dose of IFX/Vedo, if changed since previous infusion.
- Concomitant therapies, if changed since previous appointment
- Routine laboratory parameters (hemoglobin, leukocytes, neutrophils, eosinophiles, basophiles, monocytes, lymphocytes, erythrocyte sedimentation rate, CRP, ferritin, iron and transferrin)
- Assessment of serum levels of IFX/Vedo (prior to infusion)
- Assessment of anti-drug antibodies of IFX/Vedo (prior to infusion)
- Assessment of fecal calprotectin levels (prior to infusion)
- Patient reported outcomes (Harvey Bradshaw Index - CD or Partial Mayo score - UC)
- Status: ongoing/discontinuation. If discontinued, reason.

* data collection is expected every 6 weeks, if required.

7.2 PATIENT REPORTED OUTCOMES

Patients will be instructed to report their health status at each data collection time point, by filling the scales online, according to the type of IBD:

- Patients with UC - Partial Mayo score (all items except for endoscopic item: stool frequency, rectal bleeding, patient's global assessment)
- Patients with CD - Harvey Bradshaw Index (5 items: general well-being, abdominal pain, number of liquid or soft stools per day, abdominal mass and complications)

The patient will be dispensed with a diary, in order to record this information between scheduled appointments.

All information will be collected anonymously.

7.3 ASSESSMENT OF SERUM ADALIMUMAB/GOLIMUMAB AND IFX/VEDOLUZIMAB LEVELS AND ANTIDRUG ANTIBODIES

Serum adalimumab/golimumab and IFX/vedoluzimab levels and antidrug antibodies will be assessed immediately prior to drug infusion and at the scheduled appointment to the hospital. Overall, each patient will have a maximum of 11 determinations (adalimumab/golimumab subset) and a maximum of 15 determinations (IFX/vedoluzimab subset). The number of determinations of serum drug levels and antidrug antibodies will depend on the treatment phase of the patients at the time of inclusion:

- Patients initiating induction with infliximab/vedoluzimab at study inclusion: 15 determinations up to week 102;
- Patients in maintenance with infliximab/vedoluzimab at study inclusion: 14 determinations until completing the 24-month follow up period;
- Patients initiating induction with adalimumab/golimumab at study inclusion: 11 determinations up to week 96;
- Patients in maintenance with adalimumab/golimumab at study inclusion: 10 determinations until completing the 24-month follow up period.

Infliximab and anti-infliximab levels

Blood from infliximab (IFX) treated patients will be collected prior to infliximab infusion. Blood will be collected to blood clotting tubes. One hour after collection, blood will be centrifuged at 10 min at 3000 RPM. Sera will be transferred into fresh tubes and stored at -20C.

Infliximab and anti-infliximab levels will be determined with an ELISA assay. Both assays employ the quantitative enzyme immunoassay technique. A monoclonal antibody specific for IFX has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any IFX present is bound by the immobilized antibody. After washing away any unbound substances, an enzyme-linked polyclonal antibody specific for IFX is added to the wells. Following a wash to remove any unbound antibody-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of IFX bound in the initial step. The color development is stopped and the intensity of the color is measured by a spectrophotometer.

Adalimumab and anti-adalimumab levels

Blood from adalimumab treated patients will be collected prior adalimumab infusion. Blood will be collected to blood clotting tubes. One hour after collection, blood will be centrifuged at 10 min at 3000 RPM. Serum will be transferred into fresh tubes and stored at -20C.

Adalimumab and anti-adalimumab levels will be determined with an ELISA assay. Both assays employ the quantitative enzyme immunoassay technique. A monoclonal antibody specific for adalimumab has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any adalimumab present is bound by the immobilized antibody. After washing away any unbound substances, an enzyme-linked polyclonal antibody specific for adalimumab is added to the wells. Following a wash to remove any unbound antibody-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of adalimumab bound in the initial step. The color development is stopped and the intensity of the color is measured by a spectrophotometer.

7.4 ASSESSMENT OF BIOLOGICAL MARKER - FECAL CALPROTECTIN

Fecal calprotectin is not routinely assessed in the medical practice and therefore is not collected in the GEDII Registry.

In this study, a stool sample will be collected during the scheduled appointment at the same time points as the collection of blood samples for serum drug levels and antidrug antibodies. Similarly, the fecal sample should be collected prior the administration of anti-TNF-alfa (adalimumab/golimumab or infliximab) or vedoluzimab.

The collected stools sample will be sent immediately to the laboratory at room temperature for extraction. Stools can be store up to 6 days at room temperature. After 6 days, stools must be extracted. One gram of stool is enough for calprotectin detection.

Stools will be weighted and extracted with extraction buffer delivered with commercial kit.

After extraction and before storage, samples will be centrifuged (5 min at 3000xg). Once centrifuged, supernatant must be transferred into a fresh tube. Undiluted extracts can be stored at -20°C for at least 4 months. Extracts must be diluted prior to analysis.

Calprotectin from diluted samples will be determined with an ELISA assay. Calprotectin wells are coated with monoclonal antibodies against calprotectin. Calprotectin present in patient samples binds to calprotectin antibody in the coating. After washing the unbound components, an anti-human calprotectin enzyme-labeled (calprotectin conjugate) is added to give a complex conjugate calprotectin antibody. After incubation, unbound conjugate is washed and removed, and the complex is incubated with a developing solution. Stops solution ends reaction and fluorescence in the wells is read. A standard curve allows the determination of calprotectin concentration in the sample.

The fecal samples will be analyzed by a Central Laboratory (Dept. de Farmacologia FMUP), using Quantum Blue. Report with the results will be provided to Investigators by mail.

8 EXPOSURE OF INTEREST

Adalimumab (Humira), golimumab (Simponi) infliximab (Remicade) and vedoluzimab (Entyvio) are the exposures of interest. These products will be used according to the approved label.

Adalimumab (Humira) is administered by subcutaneous infusion:

- **Crohn's disease (induction):** 160 mg at Day 1, 80 mg at week 2, 40mg at week 4, then every 2 weeks.
- **Ulcerative Colitis (induction):** 160 mg at Day 1, 80 mg at week 2, 40mg week 4, then every 2 weeks.
- **Crohn's disease (maintenance):** 40 mg every 2 weeks or 40 mg every week
- **Ulcerative colitis (maintenance):** 40 mg every 2 weeks or 40 mg every week

Golimumab (Simponi) is administered by subcutaneous infusion:

- **Ulcerative Colitis (induction):** 200 mg at Day 1, 100 mg at week 2, 50 mg week 4, then every 4 weeks.
- **Ulcerative colitis (maintenance):** 50 mg or 100 mg every 4 weeks.

Infliximab (Remicade) is administered by intravenous infusion:

- **Crohn's disease (induction):** 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.
- **Ulcerative Colitis (induction):** 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.
- **Crohn's disease (maintenance):** 5 mg/kg or 10 mg/kg every 8 weeks or every 6 weeks (if required)
- **Ulcerative colitis (maintenance):** 5 mg/kg or 10 mg/kg every 8 weeks or every 6 weeks (if required)

Vedoluzimab (Entyvio) is administered by intravenous infusion:

- **Crohn's disease (induction):** 300 mg at 0, 2 and 6 weeks, then every 8 weeks.
- **Ulcerative Colitis (induction):** 300 mg at 0, 2 and 6 weeks, then every 8 weeks.
- **Crohn's disease (maintenance):** 300 mg every 8 weeks.
- **Ulcerative colitis (maintenance):** 300 mg every 8 weeks.

9 ENDPOINTS

9.1 PRIMARY ENDPOINT

In the subset of biologic-naïve and non-naïve patients with active, moderate to severe CD receiving adalimumab:

- **Fecal calprotectin** levels and **serum adalimumab levels** at each data collection time points
- **Fecal calprotectin** levels and presence of **anti-adalimumab antibodies (+ or -)** at each data collection time points

In the subset of biologic-naïve and non-naïve patients with active, moderate to severe CD receiving IFX/Vedo:

- **Fecal calprotectin** levels and **serum IFX/Vedo levels** at each data collection time points
- **Fecal calprotectin** levels and presence of **anti-IFX/anti-Vedo antibodies (+ or -)** at each data collection time points

In the subset of biologic-naïve and non-naïve patients with active, moderate to severe UC receiving adalimumab/golimumab:

- **Fecal calprotectin** levels and **serum adalimumab/golimumab levels** at each data collection time points
- **Fecal calprotectin** levels and presence of **anti-adalimumab/anti-golimumab antibodies (+ or -)** at each data collection time points

In the subset of biologic-naïve and non-naïve patients with active, moderate to severe UC receiving IFX/Vedo:

- **Fecal calprotectin** levels and **serum IFX/Vedo levels** at each data collection time points
- **Fecal calprotectin** levels and presence of **anti-IFX/anti-Vedo antibodies (+ or -)** at each data collection time points

9.2 SECONDARY ENDPOINTS

In the subset of biologic-naïve and non-naïve patients with active, moderate to severe CD receiving adalimumab:

- Serum **adalimumab levels** and **anti-adalimumab antibodies (+ or -)** at each data collection time points.
- Serum **adalimumab levels** and **clinical activity (HBI)** at each data collection time points.
- **Anti-adalimumab antibodies (+ or -)** and **clinical activity (HBI)** at each data collection time points.
- Serum **adalimumab levels** and patient-reported **clinical activity (Patient reported HBI)** at each data collection time points.
- **Anti-adalimumab antibodies (+ or -)** and patient-reported **clinical activity (Patient reported HBI)** at each data collection time points.
- **Therapeutics administered** for CD (name and dose) and serum **adalimumab levels**.
- **Therapeutics administered** for CD (name and dose) and **anti-adalimumab antibodies (+ or -)**.

In the subset of biologic-naïve and non-naïve patients with active, moderate to severe CD receiving IFX/Vedo:

- Serum **IFX/Vedo levels** and **anti-IFX/anti-Vedo antibodies (+ or -)** at each data collection time points
- Serum **IFX/Vedo levels** and **clinical activity (HBI)** at each data collection time points.
- **Anti-IFX/anti-Vedo antibodies (+ or -)** and **clinical activity (HBI)** at each data collection time points.
- Serum **IFX/Vedo levels** and patient-reported **clinical activity (Patient reported HBI)** at each data collection time points.
- **Anti-IFX/anti-Vedo antibodies (+ or -)** and patient-reported **clinical activity (Patient reported HBI)** at each data collection time points.
- **Therapeutics administered** for CD (name and dose) and serum **IFX/Vedo levels**.

- **Therapeutics administered** for CD (name and dose) and **anti-IFX/anti-Vedo antibodies** (+ or -).

In the subset of biologic-naïve and non-naïve patients with active, moderate to severe UC receiving adalimumab/golimumab:

- Serum **adalimumab/golimumab levels** and **anti-adalimumab/anti-golimumab antibodies (+ or -)** at each data collection time points
- Serum **adalimumab/golimumab levels** and **clinical activity (partial Mayo Score)** at each data collection time points.
Partial Mayo Score: Mayo score excluding the endoscopy subscore (range: 0-9).
- **Anti-adalimumab/anti-golimumab antibodies (+ or -)** and **clinical activity (partial Mayo Score)** at each data collection time points.
- Serum **adalimumab/golimumab levels** and patient-reported **clinical activity (Patient reported partial Mayo Score)** at each data collection time points.
- **Anti-adalimumab/anti-golimumab antibodies (+ or -)** and patient-reported **clinical activity (Patient reported partial Mayo Score)** at each data collection time points.
- **Therapeutics administered** for UC (name and dose) and serum **adalimumab/golimumab levels**.
- **Therapeutics administered** for UC (name and dose) and **anti-adalimumab/anti-golimumab antibodies** (+ or -)

In the subset of biologic-naïve and non-naïve patients with active, moderate to severe UC receiving IFX/Vedo:

- Serum **IFX/Vedo levels** and **anti-IFX/anti-Vedo antibodies (+ or -)** at each data collection time points
- Serum **IFX/Vedo levels** and **clinical activity (partial Mayo Score)** at each data collection time points.
Partial Mayo Score: Mayo score excluding the endoscopy subscore (range: 0-9).
- **Anti-IFX/anti-Vedo antibodies (+ or -)** and **clinical activity (partial Mayo Score)** at each data collection time points.
- Serum **IFX/Vedo levels** and patient-reported **clinical activity (Patient reported partial Mayo Score)** at each data collection time points.
- **Anti-IFX/anti-Vedo antibodies (+ or -)** and patient-reported **clinical activity (Patient reported partial Mayo Score)** at each data collection time points.
- **Therapeutics administered** for UC (name and dose) and serum **IFX/Vedo levels**.

- **Therapeutics administered** for UC (name and dose) and **anti-IFX/anti-Vedo antibodies** (+ or -)

In the subsets of biologic-naïve and non-naïve patients patients with active, moderate to severe CD receiving adalimumab + azathioprine or adalimumab + methotrexate or IFX/Vedo + azathioprine or IFX/Vedo + methotrexate:

- **Fecal calprotectin** levels and **serum adalimumab levels** at each data collection time points
- **Fecal calprotectin** levels and presence of **anti-adalimumab antibodies (+ or -)** at each data collection time points
- **Fecal calprotectin** levels and **serum IFX/Vedo levels** at each data collection time points
- **Fecal calprotectin** levels and presence of **anti-IFX/anti-Vedo antibodies (+ or -)** at each data collection time points

In the subsets of biologic-naïve and non-naïve patients with active, moderate to severe UC receiving adalimumab/golimumab + azathioprine or adalimumab/golimumab + methotrexate or IFX/Vedo + azathioprine or IFX/Vedo+ methotrexate:

- **Fecal calprotectin** levels and **serum adalimumab/golimumab levels** at each data collection time points
- **Fecal calprotectin** levels and presence of **anti-adalimumab/anti-golimumab antibodies (+ or -)** at each data collection time points
- **Fecal calprotectin** levels and **serum IFX/Vedo levels** at each data collection time points
- **Fecal calprotectin** levels and presence of **anti-IFX/anti-Vedo antibodies (+ or -)** at each data collection time points

In the subset of biologic-naïve and non-naïve patients with active, moderate to severe CD:

- **Physician's reported HBI** and **patient-reported HBI** (overall and according to anti-TNF-alfa or vedoluzimab)

In the subset of biologic-naïve and non-naïve patients with active, moderate to severe UC:

- **Physician's reported partial Mayo Score** at each data collection time points and **patient-reported partial Mayo Score** (overall and according to anti-TNF-alfa or vedoluzimab)

9.3 DEFINITIONS OF INTEREST

Clinical activity

Crohn's disease⁴⁰

- Clinical response in patients with CD: 3-point reduction in the Harvey-Bradshaw Index (HBI) at week 2 (infliximab/vedoluzimab) or week 6 (adalimumab) after induction therapy
- Clinical remission among patients with CD: HBI \leq 4 points during maintenance therapy with adalimumab or IFX/vedoluzimab
- Clinically active disease among patients with CD: HBI $>$ 4 points during maintenance therapy with adalimumab or IFX/vedoluzimab:
 - Mildly active disease: HBI of 5–7,
 - Moderately active disease: HBI of 8–16
 - Severely active disease: HBI \geq 17
- Clinical relapse among patients with CD: HBI \geq 8 or an increase of $>$ 3 points in HBI to at least an HBI of 5 points.

Ulcerative colitis

- Clinical response: defined as a 3-point reduction in Partial Mayo score or more at week 2 after induction therapy with adalimumab/golimumab or IFX/vedoluzimab.
Partial Mayo Score: Mayo score excluding the endoscopy subscore (range: 0-9)
- Clinical remission: defined as Partial Mayo score=0 during maintenance therapy with adalimumab/golimumab or IFX/vedoluzimab.⁴¹
- Clinical relapse disease among patients with UC: Partial Mayo score \geq 3 during maintenance therapy with adalimumab/golimumab or IFX/vedoluzimab.⁴¹

Biologic naïve patients:

Patients who had never received biologic therapy prior to study inclusion in the study.

Biologic non-naïve patients:

Patients who are receiving maintenance therapy with adalimumab/golimumab or infliximab/vedoluzimab at the time of study inclusion.

Definition of Observation period

- Start of observation period – corresponds to the date of the first appointment of the study.
- End observation period – 24 months after the start of the observation period.

Harvey Bradshaw Index (assessment of Crohn's Disease activity)**1. General well-being (yesterday)**

0 = Very well

1 = Slightly below par

2 = Poor

3 = Very poor

4 = Terrible

2. Abdominal pain (yesterday)

0 = None

1 = Mild

2 = Moderate

3 = Severe

3. Number of liquid or soft stools per day (yesterday) = _____

4. Abdominal mass

0 = None

1 = Dubious

2 = Definite

3 = Definite and tender

5. Complications (check any that apply; score one per item except for first box)

- None
- Arthralgia
- Uveitis
- Erythema nodosum
- Aphthous ulcers
- Pyoderma gangrenosum
- Anal fissure
- New fistula
- Abscess

Partial Mayo scoring system (assessment of ulcerative colitis clinical activity)

Stool frequency^a

0 = Normal number of stools for this patient

1 = 1-2 stools more than normal

2 = 3-4 stools more than normal

3 = 5 or more stools more than normal

Rectal bleeding^b

0 = No blood seen

1 = Streaks of blood with stool less than half the time

2 = Obvious blood with stool most of the time

3 = Blood alone passed

Physician's global assessment^c

0 = Normal

1 = Mild disease

2 = Moderate disease

3 = Severe disease

^a Each patient serves as his or her own control to establish the degree of abnormality of the stool frequency.

^b The daily bleeding score represents the most severe bleeding of the day.

^c The physician's global assessment acknowledges the 3 other criteria, the patient's recall of abdominal discomfort and general sense of well-being, and other observations, such as physical findings and the patient's performance status.

10 STATISTICAL ANALYSIS

10.1 GENERAL CONSIDERATIONS

All quantitative variables will be summarized through descriptive statistics namely mean, median, standard deviation and range (minimum and maximum) and qualitative variables through absolute (n) and relative frequencies (%) and 95% confidence intervals (if applicable). The statistical analysis will be performed through frequency tables for qualitative variables and tables with descriptive statistics for quantitative variables.

The association between two quantitative variables will be performed through Pearson correlation coefficient or Spearman correlation coefficient, in case the normality assumption is not verified.

The association of two categorical variables will be tested through the Chi-Square test or Fisher Exact test (if applicable).

The comparison of two independent samples in respect to quantitative variables will be performed through t-test for independent samples or the Mann-Whitney non-parametric test, according to the assumption validations of the statistical test (if applicable).

The association between quantitative variables and a categorical binary variable will be analyzed by Area Under the ROC Curve.

The concordance kappa will be used for binary variables, if applicable.

For each subset, the proportion of patients with active disease, clinical response, clinical remission (physician and patient reported HBI or Partial Mayo), presence of anti-drug antibodies at each data collection time points will be summarized using 95% confidence intervals.

Results for hemoglobin, leukocytes, neutrophils, eosinophiles, basophiles, monocytes, lymphocytes, erythrocyte sedimentation rate, CRP, ferritin, iron, transferrin, fecal calprotectin, serum levels of adalimumab/golimumab and IFX/vedoluzimab, will be summarized by total number of observations (n), mean, median, standard deviation, minimum and maximum.

Exploratory Generalized Estimated Equations with AR1 correlation structure in time, to account for the within-subject correlations, will be used to explore the association between fecal calprotectin levels and serum drug levels (dependent variable) as well as the association of fecal calprotectin levels with the presence of antidrug antibodies (dependent variable), throughout the follow up period.

The impact of immunogenicity on the efficacy of adalimumab/golimumab or IFX/vedoluzimab will also be exploratory assessed by associating serum drug levels and anti-drug antibodies in respect to the outcomes, need for dose escalation, and discontinuation rate at the predetermined time points.

Therapeutics used will be compared with mean serum drug levels and presence/absence of anti-drug antibodies at each data collection through a descriptive analysis.

10.2 SAMPLE SIZE

The sample size is not based on formal statistical assumptions. This exploratory study will analyze all patients who are registered in the GEDII Registry and meet this study's eligibility criteria, during a recruitment period of 12 months. In this circumstance, it is expected to analyze a total of 400 patients. This sample will allow a descriptive analysis of clinical characteristics among pre-defined subsets. Furthermore, this sample will allow the exploratory analysis of correlations between independent variables and outcomes of interest within subsets during the follow period.

11 PHARMACOVIGILANCE

New safety findings that can potentially affect the risk/benefit profile of a medicinal product identified during the conduct of epidemiological studies will be reported promptly to the Health Authorities, according to local pharmacovigilance regulations.

12 ETHICAL AND LEGAL ASPECTS

12.1 ETHICS

The study will be conducted according to the ethics principles originated from the Declaration of Helsinki and the Portuguese Clinical Research law (Law #21/2014, 16th April 2014).⁴²

A copy of the protocol, proposed informed consent form and other written subject information will be submitted to the competent Ethics Committee for written approval. A copy of the written approval of the protocol and informed consent form must be received by the Investigator before recruitment of subjects and data collection.

The investigator will submit and, where necessary, obtain approval from the competent Ethics Committee for all subsequent protocol amendments and changes to the informed consent document.

12.2 INFORMED CONSENT

Before any protocol specific procedures are performed, the investigator is responsible for obtaining written informed consent from the subject (or authorized representative) and after an adequate and clear explanation of the aims, methods, anticipated benefits, and potential hazards of the study.

The informed consent process should be documented in the subject's medical charts, and the informed consent form should be signed and personally dated by the subject (or authorized representative, if applicable) and by the person who conducted the informed consent discussion (not necessarily an investigator). The original signed informed consent form should be retained in accordance with institutional policy, and a copy of the signed consent form should be provided to the subject or authorized representative.

12.3 STUDY DISCONTINUATION CRITERIA

Premature termination of this study may occur because of a regulatory authority decision, change in opinion of the ethics committee, or at the discretion of the GEDII. If GEDII decides to terminate prematurely the study, GEDII or designee will promptly notify the appropriate IEC and regulatory authority (if applicable).

13 QUALITY CONTROL

The study will involve a GEDII monitor who will be responsible to ensure that the study is conducted according to the protocol and to the local regulatory/ethical requirements.

Before the start of activities a study monitor will conduct initiation Visits at the sites in order to train the investigational team on the protocol and other protocol-related procedures.

During the study the monitor will also be responsible for conducting periodic monitoring visits at the sites to ensure that the protocol is being followed and the data recorded is accurate and collected according to the defined procedures.

The sites may be subject to review by the Independent Ethics Committee and/or to quality assurance audits performed by GEDII designated representative, and/or to inspection by appropriate regulatory authorities. The Investigator(s) and their relevant staff should be available during the monitoring visits and possible audits or inspections. The investigator and institution will allow the appropriate regulatory authorities direct access to source documents to perform this verification.

Prior to study start, the investigator is required to sign a protocol signature page confirming his/her agreement to conduct the study in accordance with this protocol and to give access to all relevant data and records to monitors, auditors, Ethics Committees, and regulatory authorities, as required.

All investigators and study staff will receive training on the protocol and other protocol-related procedures prior to start of activities. The training will be provided by the GEDII or its representative.

14 DATA HANDLING

14.1 CONFIDENTIALITY

The investigator is responsible for ensuring that the subject's confidentiality is maintained.

Questionnaires, database and other documents generated in this study will be identified by a unique subject identification number only. This 2-digit number will be assigned sequentially by each investigator, based on subject's recruitment schedule (e.g.: first subject will be assigned No. 01, the second subject will be No. 02 and so on). Each center will also be assigned a predefined two-digit number.

The GEDII Registry received the authorization of Comissão Nacional para Protecção de Dados for the purpose of data processing under the scope of "Lei de Protecção de Dados de Carácter Pessoal Dec. 67/98 de 26 de Outubro".

14.2 DATA COLLECTION

All study data will be obtained from the GEDII Registry, laboratory reports and, when relevant, will be complemented by subject's interview or other medical sources (as appropriate).

The investigator will be responsible for ensuring that all findings and data are accurately and reliably recorded in the case report form.

All eligible subjects who are not enrolled in the study will be recorded in a specific form. No personal data will be collected in this form, only the date of assessment of eligibility criteria and reason for non-enrollment. This form will be kept exclusively at each site.

14.3 STUDY ARCHIVE

The investigator will keep an adequate archive of all study documentation with access restricted to study team. The study archive will be kept at each site for at least 15 years from the study close out.

14.4 PUBLICATION POLICY

All documents and results generated from this clinical study are exclusive property of Coordinating Investigator and GEDII. Any related publications must be previously approved in written by the Coordinating Investigator and GEDII.

The results of the study will be presented by the Coordinating Investigator in national and international meetings and will be published in international papers.

The study results can only be published after the clinical study is terminated, the data analysis is completed and **only** upon the agreement of the study's scientific board. The publication should include the results from all the centers which have participated in the clinical investigation, The publication of results should be agreed by all participating investigators and in strict adherence to the principles originated from the Helsinki Declaration and according to Portuguese Clinical Research law (Law #21/2014, 16th April 2014).⁴²

Authorship criteria

For all publications related to this study, the GEDII will comply with recognized ethical standards concerning publications and authorship established by the International Committee of Medical Journal Editors (*Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals - Updated December 2013*).

For all publications related with this clinical study, the order of the authors is as follows:

- The first author position will correspond to the Coordinating Investigator;
- The subsequent author's positions will correspond to the principal investigator from each center, who will be ranked decreasingly according to the number of patients included in the study, as far as the number of co-authors allowed by the journal is not exceeded;
- All the participating investigators not figuring in the authorship (due to journal's limitations in the number of co-authors) will be cited in the acknowledgment section of the publication.
- The last author position will correspond to a GEDII member.

15 REFERENCES

1. Magro F, Portela F. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. *BioDrugs*. 2010;24 Suppl 1:3-14.
2. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. *Lancet*. 2007;369(9573):1641-57.
3. Azevedo LF, Magro F, Portela F, Lago P, Deus J, Cotter J, et al. Estimating the prevalence of inflammatory bowel disease in Portugal using a pharmaco-epidemiological approach. *Pharmacoepidemiol Drug Saf*. 2010;19(5):499-510.
4. Bosani M, Ardizzone S, Porro GB. Biologic targeting in the treatment of inflammatory bowel diseases. *Biologics*. 2009;3:77-97.
5. Breese EJ, Michie CA, Nicholls SW, Murch SH, Williams CB, Domizio P, et al. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. *Gastroenterology*. 1994;106(6):1455-66.
6. Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. *Inflamm Bowel Dis*. 2009;15(8):1264-75.
7. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. *Gastroenterology*. 2007;132(1):52-65.
8. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. *Gastroenterology*. 2006;130(2):323-33; quiz 591.
9. Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. *Gut*. 2007;56(9):1232-9.
10. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. *Ann Intern Med*. 2007;146(12):829-38.
11. Fiorino G, Peyrin-Biroulet L, Repici A, Malesci A, Danese S. Adalimumab in ulcerative colitis: hopes and hopes. *Expert Opin Biol Ther*. 2011;11(1):109-16.
12. Oussalah A, Laclotte C, Chevaux JB, Bensenane M, Babouri A, Serre AA, et al. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. *Aliment Pharmacol Ther*. 2008;28(8):966-72.
13. Peyrin-Biroulet L, Laclotte C, Roblin X, Bigard MA. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. *World J Gastroenterol*. 2007;13(16):2328-32.
14. Danese S, Fiorino G, Reinisch W. Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-alpha therapy. *Aliment Pharmacol Ther*. 2011;34(1):1-10.
15. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. *Am J Gastroenterol*. 2009;104(3):760-7.
16. Rostholder E, Ahmed A, Cheifetz AS, Moss AC. Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis. *Aliment Pharmacol Ther*. 2012;35(5):562-7.
17. Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn's disease. *Aliment Pharmacol Ther*. 2011;33(9):987-95.
18. Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. *Gastroenterology*. 2009;137(5):1628-40.
19. Ben-Horin S, Yavzori M, Katz L, Kopylov U, Picard O, Fudim E, et al. The immunogenic part of infliximab is the F(ab')₂, but measuring antibodies to the intact infliximab molecule is more clinically useful. *Gut*. 2011;60(1):41-8.
20. Svenson M, Geborek P, Saxne T, Bendtzen K. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. *Rheumatology (Oxford)*. 2007;46(12):1828-34.
21. Baert F, Noman M, Vermeire S, Van Assche G, G DH, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. *N Engl J Med*. 2003;348(7):601-8.

22. Ben-Horin S, Mazor Y, Yanai H, Ron Y, Kopylov U, Yavzori M, et al. The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD. *Aliment Pharmacol Ther.* 2012;35(6):714-22.
23. Steenholdt C, Al-khalaf M, Brynskov J, Bendtzen K, Thomsen OO, Ainsworth MA. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease. *Inflamm Bowel Dis.* 2012;18(12):2209-17.
24. Maser EA, Vilella R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. *Clin Gastroenterol Hepatol.* 2006;4(10):1248-54.
25. Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. *Gut.* 2010;59(1):49-54.
26. Aarden L, Ruuls SR, Wolbink G. Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. *Curr Opin Immunol.* 2008;20(4):431-5.
27. Imaeda H, Andoh A, Fujiyama Y. Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease. *J Gastroenterol.* 2012;47(2):136-43.
28. Pariente B, Pineton de Chambrun G, Krzysiek R, Desroches M, Louis G, De Cassan C, et al. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. *Inflamm Bowel Dis.* 2012;18(7):1199-206.
29. Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. *Am J Gastroenterol.* 2008;103(4):944-8.
30. Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. *Gut.* 2007;56(9):1226-31.
31. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? *Gut.* 2006;55(3):426-31.
32. Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Farkkila M. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. *Inflamm Bowel Dis.* 2008;14(1):40-6.
33. Xiang JY, Ouyang Q, Li GD, Xiao NP. Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis. *World J Gastroenterol.* 2008;14(1):53-7.
34. von Roon AC, Karamountzos L, Purkayastha S, Reese GE, Darzi AW, Teare JP, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. *Am J Gastroenterol.* 2007;102(4):803-13.
35. Sipponen T, Bjorkesten CG, Farkkila M, Nuutinen H, Savilahti E, Kolho KL. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. *Scand J Gastroenterol.* 2010;45(3):325-31.
36. Sipponen T, Savilahti E, Karkkainen P, Kolho KL, Nuutinen H, Turunen U, et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. *Inflamm Bowel Dis.* 2008;14(10):1392-8.
37. Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. *Scand J Gastroenterol.* 2004;39(10):1017-20.
38. Mao R, Xiao YL, Gao X, Chen BL, He Y, Yang L, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. *Inflamm Bowel Dis.* 2012;18(10):1894-9.
39. Van Assche G, Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez M, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. *J Crohns Colitis.* 2010;4(1):7-27.
40. Best WR. Predicting the Crohn's disease activity index from the Harvey-Bradshaw Index. *Inflamm Bowel Dis.* 2006;12(4):304-10.
41. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. *N Engl J Med.* 1987;317(26):1625-9.
42. Lei da Investigação Clínica. Diário da República, 1.ª série - N.º 75 - 16 de abril de 2014.

APPENDIX – CRONOGRAM A (CD or UC patients receiving adalimumab or UC patients receiving golimumab)

	Adalimumab/Golimumab											
	Induction period			Maintenance period data collection time points (24-month follow up)								
Information to be collected	Day1 or basal	W 2	W 6	W 12	W 24	W 36	W 48	W 60	W 72	W 84	W 96	
Date of birth	X ⁴											
Sex	X ⁴											
Height	X ⁴											
Weight	X	X	X	X	X	X	X	X	X	X	X	X
BMI	X	X	X	X	X	X	X	X	X	X	X	X
Smoking status	X ⁴											
Medical history	X ⁴											
Comorbidities	X	X	X	X	X	X	X	X	X	X	X	X
Disease presentation	X ⁴											
Diagnosis (UC or CD) – location, steroid behavior, prognostic classification)	X ⁴											
Clinical activity (HBI / Partial Mayo)	X	X	X	X	X	X	X	X	X	X	X	X
Dose of adalimumab/golimumab administered	X	X	X	X	X	X	X	X	X	X	X	X
Concomitant therapies	X	X	X	X	X	X	X	X	X	X	X	X
Routine laboratory parameters	X	X	X	X	X	X	X	X	X	X	X	X
Serum levels (adalimumab/golimumab) ¹	X	X	X	X	X	X	X	X	X	X	X	X
Anti-drug antibodies (adalimumab/golimumab) ¹	X	X	X	X	X	X	X	X	X	X	X	X
Fecal sample (calprotectin levels) ²	X	X	X	X	X	X	X	X	X	X	X	X
Patient reported outcomes (HBI or Partial Mayo)	X	X	X	X	X	X	X	X	X	X	X	X

The data collection time points during maintenance with adalimumab/golimumab are expected every 8 weeks until completing the 24-month follow up period

¹ Blood sample to be collected prior to each infusion of adalimumab/golimumab at the scheduled appointment (approximately every 12 weeks during maintenance period). Sample will be analyzed by Central Laboratory.

² Stool sample to be collected prior to each infusion of adalimumab/golimumab at the scheduled appointment (approximately every 12 weeks during maintenance period). Sample will be analyzed by Central Laboratory.

³ Patients in maintenance with adalimumab/golimumab at study inclusion will be followed every 12 weeks until completing the 24-month follow up period.

⁴ Basal data to be collected, regardless of the patient's treatment phase at study inclusion.

W = week. HBI = Harvey Bradshaw Index.